Soligenix, Inc. (SNGX) Enters into Commercial Collaboration with SciClone Pharmaceuticals in China for SGX942
Soligenix, a clinical-stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures, has established a personalized medicine collaboration with SciClone Pharmaceuticals in SNGX’s oral mucositis clinical program with SGX942 for the treatment of oral mucositis (OM). Soligenix is developing SGX942 to address the unmet medical need of OM in solid tumor patients, especially those with head and neck cancer. OM affects approximately 90,000 head and neck cancer patients each year in the U.S. SGX942 recently received investigational new drug (IND) clearance from the U.S. Food and Drug Administration (FDA) and is prepared to initiate a phase…